Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Going to college has consistently conferred a large wage premium. We show that the relative premium received by lower-income Americans has halved since 1960. We decompose this steady rise in ...

Figure 1. Overview of ICARus pipeline. (A) Pipeline diagram overview of ICARus. (B) The input for ICARus is a (Genes x Samples) normalized gene expression matrix where the rows are gene symbols (IDs) ...

Biogen has initiated the BRAVE study, a global Phase 3 clinical trial to evaluate omaveloxolone in children with Friedreich ataxia, addressing a critical unmet need in the pediatric population.

And when we take into account its pipeline and the recent deals it's made, Novo Nordisk looks even more promising -- the weight-management market is on an incredible growth path.

Home / Opinion / Staff Columnists Reynolds saved a pipeline for her people Todd Dorman Jun. 18, 2025 6:14 am, Updated: Jun. 18, 2025 8:01 am ...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia Provided by GlobeNewswire Jun 18, 2025, 4:30:27 AM ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...

According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.

Notably, Biogen Inc. (NASDAQ:BIIB) anticipates that its Fit for Growth program will result in net cost reductions of $800 million by the end of the year. The company is currently focusing on nine ...

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback.